Complete Filing Data
Incannex Healthcare Inc. reported Stockholders Equity of $20.83 million for FY2023.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Incannex Healthcare Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income * | -$46.9M | -$18.5M | -$48.8M | -$14.9M | -$11.4M | -$4.7M |
| Revenue * | $86.0K | $12.0K | ||||
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | $208.0K | -$77.0K | -$2.3M | |||
| Comprehensive Income Net Of Tax | -$46.7M | -$18.5M | -$51.1M | |||
| Operating Income Loss | -$23.8M | -$30.0M | -$49.7M | |||
| Operating Expenses | $23.9M | $30.1M | $49.7M | |||
| Nonoperating Income Expense | -$23.1M | $11.6M | $857.0K | |||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$46.9M | -$18.4M | -$48.8M | |||
| General And Administrative Expense | $13.1M | $17.2M | $8.0M | |||
| Research And Development Expense | $10.7M | $12.9M | $6.3M | $5.4M | $4.7M | $2.1M |
| Interest Expense Nonoperating | $303.0K | |||||
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $208.0K | -$77.0K | ||||
| Profit Loss Before Tax | -$20.0M | -$14.9M | -$11.4M | -$3.9M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$6.5M | -$6.4M | -$4.0M | -$5.9M | -$5.4M | -$6.0M | -$5.2M | -$726.0K | -$3.6M | -$2.9M |
| Revenue * | $12.0K | $74.0K | ||||||||
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | -$287.0K | $223.0K | -$88.0K | -$414.0K | $339.0K | -$820.0K | $927.0K | -$510.0K | -$202.0K | $3.7M |
| Comprehensive Income Net Of Tax | -$6.8M | -$6.2M | -$4.1M | -$6.3M | -$5.1M | -$6.9M | -$4.3M | -$1.2M | -$3.8M | $766.0K |
| Operating Income Loss | -$7.0M | -$6.8M | -$5.0M | -$5.0M | -$6.3M | -$7.4M | -$8.0M | -$4.9M | -$3.7M | -$3.6M |
| Operating Expenses | $7.0M | $6.8M | $5.0M | $5.0M | $6.3M | $7.4M | $8.0M | $4.9M | $3.7M | $3.6M |
| Nonoperating Income Expense | $474.0K | $387.0K | $1.0M | -$890.0K | $834.0K | $1.4M | $2.7M | $4.2M | $80.0K | $721.0K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$6.5M | -$6.4M | -$4.0M | -$5.9M | -$5.4M | -$6.0M | -$5.2M | -$726.0K | -$3.6M | -$2.9M |
| General And Administrative Expense | $4.7M | $5.7M | $2.3M | $3.6M | $3.4M | $4.1M | $5.3M | $2.3M | $2.0M | $2.1M |
| Research And Development Expense | $2.3M | $1.1M | $2.7M | $1.4M | $2.9M | $3.3M | $2.6M | $2.6M | $1.6M | $1.5M |
| Interest Expense Nonoperating | -$5.0K | -$5.0K | $132.0K | -$28.0K | -$28.0K | |||||
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -$287.0K | $223.0K | -$88.0K | -$414.0K | $339.0K | |||||
| Profit Loss Before Tax |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Stockholders Equity | $20.8M | $24.7M | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $22.1M | $25.8M | ||||
| Liabilities | $5.8M | $3.0M | $2.0M | $755.0K | $1.1M | |
| Assets | $17.0M | $23.8M | $37.9M | $9.3M | $4.2M | |
| Retained Earnings Accumulated Deficit | -$110.7M | -$92.2M | ||||
| Prepaid Expense And Other Assets Current | $507.0K | $877.0K | ||||
| Liabilities Current | $5.6M | $2.6M | ||||
| Liabilities And Stockholders Equity | $17.0M | $23.8M | ||||
| Common Stock Value | $2.0K | $2.0K | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $8.9M | -$16.1M | -$2.9M | |||
| Cash And Cash Equivalents At Carrying Value | $5.9M | $22.1M | ||||
| Assets Current | $16.2M | $23.0M | ||||
| Accounts Payable And Other Accrued Liabilities Current | $612.0K | $689.0K | ||||
| Property Plant And Equipment Net | $472.0K | $294.0K | ||||
| Operating Lease Right Of Use Asset | $373.0K | $492.0K | ||||
| Operating Lease Liability Noncurrent | $210.0K | $408.0K | ||||
| Operating Lease Liability Current | $163.0K | $113.0K | ||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$3.3M | -$3.3M | ||||
| Other Receivables Net Current | $9.8M | |||||
| Equity | $20.8M | $24.7M | ||||
| Accrued Liabilities And Other Liabilities | $4.8M | |||||
| Accounts Payable Other Current | $612.0K | $1.7M | ||||
| Increase Decreasein RD Tax Incentive Receivable | -$5.6M | $9.8M | ||||
| Cash And Cash Equivalents | $33.4M | $37.5M | $9.1M | $3.6M | ||
| Trade And Other Current Receivables | $287.5K | $294.7K | $169.1K | $413.3K | ||
| Trade And Other Current Payables | $3.7M | $2.0M | $755.0K | $955.0K | ||
| Other Current Assets | $1.0M | $84.0K | $36.1K | $36.3K | ||
| Net Assets Liabilities | $84.1M | $35.9M | $8.6M | $3.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $73.4M | $77.0M | $13.4M | $7.4M | $964.0K | $6.6M | $11.2M | $14.1M | $18.9M | $19.8M | $24.7M | $27.9M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $69.2M | $73.3M | $15.0M | $6.7M | $2.1M | $3.6M | $5.9M | $9.3M | $14.6M | $16.3M | $24.9M | $28.1M |
| Liabilities | $1.6M | $1.7M | $7.1M | $8.8M | $10.1M | $9.5M | $3.1M | $3.5M | ||||
| Assets | $75.0M | $78.7M | $20.4M | $16.2M | $11.1M | $16.0M | $17.3M | $22.4M | ||||
| Retained Earnings Accumulated Deficit | -$170.5M | -$164.0M | -$157.6M | -$126.0M | -$122.0M | -$116.1M | -$104.2M | -$98.2M | ||||
| Prepaid Expense And Other Assets Current | $431.0K | $486.0K | $791.0K | $416.0K | $417.0K | $489.0K | $7.0M | $6.8M | ||||
| Liabilities Current | $1.5M | $1.6M | $7.0M | $7.4M | $5.8M | $9.2M | $2.9M | $3.2M | ||||
| Liabilities And Stockholders Equity | $75.0M | $78.7M | $20.4M | $16.2M | $11.1M | $16.0M | $17.3M | $22.4M | ||||
| Common Stock Value | $36.0K | $35.0K | $20.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $58.0M | -$2.2M | ||||||||||
| Cash And Cash Equivalents At Carrying Value | $68.9M | $73.3M | $15.0M | $6.7M | $2.1M | $3.6M | $9.3M | $14.6M | ||||
| Assets Current | $74.7M | $78.3M | $20.0M | $15.6M | $10.5M | $15.2M | $16.3M | $21.3M | ||||
| Accounts Payable And Other Accrued Liabilities Current | $1.3M | $1.3M | $6.1M | $1.1M | $845.0K | $1.6M | $1.4M | $1.1M | ||||
| Property Plant And Equipment Net | $108.0K | $168.0K | $227.0K | $277.0K | $273.0K | $428.0K | $523.0K | $559.0K | ||||
| Operating Lease Right Of Use Asset | $163.0K | $212.0K | $258.0K | $291.0K | $329.0K | $411.0K | $408.0K | $468.0K | ||||
| Operating Lease Liability Noncurrent | $53.0K | $64.0K | $74.0K | $104.0K | $152.0K | $221.0K | $248.0K | $301.0K | ||||
| Operating Lease Liability Current | $110.0K | $146.0K | $184.0K | $186.0K | $177.0K | $190.0K | $161.0K | $169.0K | ||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$3.2M | -$2.9M | -$3.1M | -$3.5M | -$3.4M | -$3.0M | -$3.7M | -$2.8M | ||||
| Other Receivables Net Current | $5.1M | $4.5M | $4.1M | $7.1M | $6.6M | $11.1M | ||||||
| Equity | $73.4M | $77.0M | $13.4M | $7.4M | $964.0K | $6.6M | $11.2M | $14.1M | $18.9M | $19.8M | $24.7M | $27.9M |
| Accrued Liabilities And Other Liabilities | $181.0K | $206.0K | $696.0K | $4.7M | $3.4M | $7.5M | ||||||
| Accounts Payable Other Current | $1.3M | $2.0M | ||||||||||
| Increase Decreasein RD Tax Incentive Receivable | $364.0K | $839.0K | $4.0M | |||||||||
| Cash And Cash Equivalents | ||||||||||||
| Trade And Other Current Receivables | ||||||||||||
| Trade And Other Current Payables | ||||||||||||
| Other Current Assets | ||||||||||||
| Net Assets Liabilities |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Share Based Compensation | $2.6M | $8.9M | $2.1M | $1.5M | $600.0K | $565.4K |
| Net Cash Provided By Used In Operating Activities | -$12.5M | -$15.8M | -$10.7M | |||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $189.0K | -$369.0K | $626.0K | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $306.0K | -$140.0K | -$824.0K | |||
| Payments To Acquire Property Plant And Equipment | $8.0K | $277.0K | $316.0K | |||
| Net Cash Provided By Used In Investing Activities | -$8.0K | -$277.0K | -$316.0K | |||
| Net Cash Provided By Used In Financing Activities | $21.4M | $8.2M | ||||
| Increase Decrease In Other Accounts Payable | $3.0M | $1.1M | ||||
| Proceeds From Issuance Of Common Stock | $48.3M | $8.2M | ||||
| Increase Decrease In Accounts Payable And Accrued Liabilities | $1.4M | $3.0M | ||||
| Increase Decrease In Acquisition Of Inprocess Research And Development | $35.3M | |||||
| Proceeds From Issuing Shares | 12.3M | 41.2M | 12.4M | 7.5M | ||
| Payments To Suppliers For Goods And Services And To And On Behalf Of Employees | $17.3M | $13.6M | $9.0M | $5.3M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|
| Share Based Compensation | $2.6M | $459.0K | $201.0K |
| Net Cash Provided By Used In Operating Activities | -$9.2M | -$2.2M | -$5.7M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$299.0K | -$177.0K | $601.0K |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $269.0K | $14.0K | |
| Payments To Acquire Property Plant And Equipment | $2.0K | $221.0K | |
| Net Cash Provided By Used In Investing Activities | -$42.0K | -$221.0K | |
| Net Cash Provided By Used In Financing Activities | $67.2M | -$52.0K | |
| Increase Decrease In Other Accounts Payable | |||
| Proceeds From Issuance Of Common Stock | $69.5M | ||
| Increase Decrease In Accounts Payable And Accrued Liabilities | -$5.4M | $3.3M | -$250.0K |
| Increase Decrease In Acquisition Of Inprocess Research And Development | |||
| Proceeds From Issuing Shares | |||
| Payments To Suppliers For Goods And Services And To And On Behalf Of Employees |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 34.5M | 16.2M | 15.4M |
| Earnings Per Share Basic | $-1.35 | $-1.15 | $-3.32 |
| Weighted Average Number Of Diluted Shares Outstanding | 34.5M | 16.2M | 15.4M |
| Earnings Per Share Diluted | $-1.35 | $-1.15 | $-3.32 |
| Common Stock Shares Issued | 1.9M | 17.6M | 15.9M |
| Common Stock Shares Authorized | 800.0M | 800.0M | 100.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | |
| Common Stock Shares Outstanding | 17.6M | 15.9M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 349.5M | 310.3M | 19.6M | 17.6M | 17.6M | 15.9M | 15.9M | 15.9M | 15.9M | 15.4M | |
| Earnings Per Share Basic | $-0.02 | $-0.02 | $-0.20 | $-0.33 | $-0.29 | $-0.38 | $-0.33 | $-0.08 | $-0.22 | $0.05 | |
| Weighted Average Number Of Diluted Shares Outstanding | 349.5M | 310.3M | 19.6M | 17.6M | 17.6M | 15.9M | 15.9M | 15.9M | 15.9M | 15.4M | |
| Earnings Per Share Diluted | $-0.02 | $-0.02 | $-0.20 | $-0.33 | $-0.29 | $-0.38 | $-0.33 | $-0.08 | $-0.22 | $0.05 | |
| Common Stock Shares Issued | 359.2M | 347.7M | 194.4M | 17.8M | 17.8M | 17.6M | 15.9M | 15.9M | |||
| Common Stock Shares Authorized | 800.0M | 800.0M | 800.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | |||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Common Stock Shares Outstanding | 359.2M | 347.7M | 194.4M | 17.8M | 17.8M | 17.6M | 12.9M | 12.9M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| RD Tax Incentive | $1.8M | $11.4M | $683.0K | |||
| Investment Income Interest | $62.0K | $206.0K | $241.0K | |||
| Foreign Currency Transaction Gain Loss Before Tax | -$289.0K | -$28.0K | -$67.0K | |||
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $2.6M | $8.9M | $2.1M | |||
| Depreciation And Amortization | $246.0K | $103.0K | $88.0K | |||
| Additional Paid In Capital | $125.2M | $116.3M | ||||
| Foreign Currency Transaction Gain Loss Unrealized | -$294.0K | -$28.0K | ||||
| Stock Issued During Period Value New Issues | $48.4M | $8.8M | ||||
| Adjustments To Additional Paid In Capital Stock Issued Issuance Costs | $2.3M | $530.0K | ||||
| Stock Issued During Period Value Share Issued To Advisors | $2.1M | |||||
| Stock Issued During Period Shares New Issues | ||||||
| Capital Reserve | $12.1M | $8.1M | $6.6M | $1.5M | ||
| Occupancy Expense | $124.6K | $112.3K | $115.8K | $2.1K | ||
| Issued Capital | $150.8M | $86.6M | $45.9M | $34.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RD Tax Incentive | $482.0K | $389.0K | $421.0K | $956.0K | $811.0K | $1.3M | $2.7M | $4.1M | -$83.0K | $666.0K | |
| Investment Income Interest | $4.0K | $28.0K | $28.0K | $75.0K | $20.0K | $71.0K | $163.0K | $55.0K | |||
| Foreign Currency Transaction Gain Loss Before Tax | -$24.0K | -$13.0K | $41.0K | -$326.0K | -$5.0K | -$11.0K | -$5.0K | -$2.0K | |||
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $2.3M | $2.6M | $416.0K | $435.0K | $459.0K | $2.1M | $3.4M | $201.0K | $531.0K | ||
| Depreciation And Amortization | $66.0K | $64.0K | $12.0K | ||||||||
| Additional Paid In Capital | $247.0M | $243.8M | $174.0M | $136.8M | $126.4M | $125.7M | $122.0M | $119.9M | |||
| Foreign Currency Transaction Gain Loss Unrealized | -$13.0K | -$5.0K | -$2.0K | ||||||||
| Stock Issued During Period Value New Issues | $2.2M | $69.5M | $10.7M | $242.0K | |||||||
| Adjustments To Additional Paid In Capital Stock Issued Issuance Costs | $91.0K | $2.3M | $747.0K | ||||||||
| Stock Issued During Period Value Share Issued To Advisors | |||||||||||
| Stock Issued During Period Shares New Issues | 10.3K | 142.4K | |||||||||
| Capital Reserve | |||||||||||
| Occupancy Expense | |||||||||||
| Issued Capital |
Most recent annual filing with the SEC: September 29, 2025
Data sourced from SEC EDGAR public filings as of August 9, 2026.